As neoadjuvant chemotherapy for advanced bladder cancer, the intra-arterial administration of methotrexate (MTX), Adriamycin (ADM), and cisplatin (CDDP; IA-MAC) was evaluated. A total of 48 patients with bladder cancer (≧T2 or CIS) were selected and received 30.1 mg MTX, 34.5 mg ADM, and 89.1 mg CDDP as an average course. The mean tumor-regression rate after 2 or 3 weeks was 52.3%, and patients with grade 3 transitional-cell carcinoma showed the best results, achieving a 69.6% regression rate. In 30 cases (63%), downstaging was observed. Among the 46 patients who underwent subsequent surgical therapy, the bladder could be preserved in 26 cases by transurethral resection or segmental resection. According to the criteria of the Japanese Association of Cancer Therapy, a histological effect of GIII or better was obtained in 15 cases (29%). The histological effect correlated well with the tumor-regression rate. As compared with intravenous therapy with MTX, vinblastine, ADM, and CDDP (M-VAC), IA-MAC treatment was well tolerated due to its lower degree of bone marrow suppression, and it resulted in a longer disease-free interval and better survival. In addition, the period prior to surgical therapy was shortened in this study. These results suggest that IA-MAC chemotherapy can be useful as an arm of multidisciplinary treatment of advanced bladder tumors.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Fukui I, Yoshida I, Oshima H (1988) Intra-arterial chemotherapy for bladder cancer. Urol Surg 1: 909
Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T, Higa I, Hayakawa M (1990) Side effects of intra-arterial M-VAC (methotrexate, vinblastine, Adriamycin and cisplatin) for advanced bladder cancer. Nishinihon J Urol 52: 439
Maatman TJ, Montie JE, Bukowski RM (1986) Intra-arterial chemotherapy as an adjuvant to surgery in transitional cell carcinoma of the bladder. J Urol 135: 256
Nakamura K, Rin M, Tamaoka K, Hashimoto H, Esaki K, Funai K, Kaminou T, Tsubakimoto M, Manabe T, Yamada T, Kobayashi N, Matsuoka T, Takashima S, Nakatsuka H, Minakuchi K, Onoyama Y (1987) Intermittent intra-arterial infusion chemotherapy for intrapelvic malignancy. Jpn J Med Radiol 47: 992
Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosl G, Morse MJ, Sogani PC, Watson RC, Dershaw DD, Reuter V, Geller N, Hollander PS, Vaughan ED Jr, Whitmore WF, Fair WR (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470
Shimosato Y, Oboshi S, Baba K (1971) Histological evaluation of effects of radiotherapy and chemotherapy in carcinoma. Jpn J Clin Oncol 1: 19
Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Pramod JM, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461
Yagoda A (1988) Neoajuvant chemotherapy in bladder cancer. Urology 26: S9
About this article
Cite this article
Kuriyama, M., Takahashi, Y., Nagatani, Y. et al. Intra-arterial administration of methotrexate, Adriamycin, and cisplatin as neoadjuvant chemotherapy for bladder cancer. Cancer Chemother. Pharmacol. 30, S1–S4 (1992). https://doi.org/10.1007/BF00686932
- Bladder Cancer